IL-17, IL-23 and IL-12/23 biologics on Prescription Blue Premium (S5584-002)
Stelara and its biosimilars, Skyrizi, Tremfya, Cosentyx and Taltz, for psoriasis, psoriatic arthritis and Crohn's, checked against this plan's 2026 formulary (its list of covered drugs).
- Plan type
- Stand-alone drug plan (PDP), Michigan
- Premium
- $106.70/month
- Deductible
- None
5 of 9 IL-17 and IL-23 biologics are covered on this plan. All 5 require prior authorization.
4 aren't on the formulary, including Selarsdi and Tremfya.
- from $2,963.28Tier 5
- from $2,470.99Tier 5
- from $9,247.21Tier 5
- from $3,161.45Tier 5
- from $10,360.13Tier 5
Not on the formulary
Selarsdi, Tremfya, Taltz, Bimzelx
Patient cost for a 30-day supply at a preferred retail pharmacy. Where the plan charges a percentage (coinsurance), the dollar figure is that share of the plan's negotiated price; "from" means other strengths cost more. Data from the CMS 2026 Part D formulary and pricing files.